Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACOVACT: Platform Trial for COVID-19 Treatments
NCT04351724Phase 3Unknown
- Sponsor
- Medical University of Vienna
- Start
- Apr 2020
- Primary completion
- Dec 2021
- Modality
- IgG Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lopinavir, ritonavir, remdesivir, rivaroxaban, candesartan and 2 more in coronavirus disease 2019 (COVID-19) (14 arms), sponsored by Medical University of Vienna. Primary endpoint: Sustained improvement (>48h) of one point on the WHO Scale at Day 29. Status: unknown.
02
Drugs
lopinavirritonavirremdesivirrivaroxabancandesartan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04351724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04351724.